SPRO

Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)

Complicated Urinary Tract Infection (cUTI)

NDA Submission

Exp Date

Q2 2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection - NDA Submission

  • ClinicalTrial.gov (NCT03788967): Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (ADAPT-PO)

WHAT IS THE NEXT CATALYST EVENT?

  • NDA Submission


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA

PRESS RELEASES

Updated by HC

SPRO, Tebipenem Pivoxil Hydrobromide, Urinary Tract Infection, UTI

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon